Chitosan/heparin sirolimus drug-eluting stent system improves anticoagulation and promotes early re-endothelialization in porcine coronary artery
10.3724/SP.J.1008.2013.01323
- Author:
Jun-Qing GAO
1
Author Information
1. Department of Cardiology, Central Hospital of Shanghai PutuoDistrict
- Publication Type:Journal Article
- Keywords:
Chitosan;
Drug-eluting stents;
Endothelialization;
Heparin;
Layer-by-layer self-assembly;
Thrombosis
- From:
Academic Journal of Second Military Medical University
2013;34(12):1323-1327
- CountryChina
- Language:Chinese
-
Abstract:
Objective To construct a sirolimus loaded drug-eluting stent (DES) using chitosan/heparin coating membrane and to explore its effect on anticoagulation and early re-endothelialization in porcine coronary artery. Methods Chitosan/heparin layer-by-layer self-assembly coating was applied to sirolimus DES, and the asymmetric applicator was used to allow for the stent blood surface to be chitosan/heparin coated and the stent vascular surface to be polylactic acid (PLA)--irolimus. The experiment was divided into bare metal stent (BMS) group, chitosan/heparin stent group, sirolimus DES group and chitosan/heparin sirolimus DES group. The anticoagulation effect of chitosan/heparin sirolimus DES was tested by arteriovenous shunt model and high load thrombosis model. The effect of chitosan/heparin sirolimus DES on early re-endothelialization was tested by 1-week long balloon injury to porcine coronary artery. Results No thrombus was found on the surfaces of chitosan/heparin sirolimus DES and chitosan/heparin stent in the arteriovenous shunt model, while the surfaces of BMS and sirolimus DES were covered with thrombus. No stent thrombosiswas found in the high load thrombosis model test of chitosan/heparin sirolimusDES and chitosan/heparin stent within 6 hours, and stent thrombosis was found in BMS at (59. 0±8. 5) min and in sirolimus DES at (67. 0 ±7. 8) min (P<0. 01). Theearly re-endothelialization test showed endothelial coverage rates of chitosan/heparin sirolimus DES and chitosan/heparin stent after 7 d implantation were (82. 7± 16. 4) % and (80. 7 ± 14. 1) %, significantly higher than those of BMS and sirolimus DES ([64. 3±11]% and [59. 8±8. 4]%, respectively; P<0. 01). Conclusion Chitosan/ heparin-coated-sirolimus DES has satisfactory anticoagulation property and it can accelerate early re-endothelialization.
